|
1
|
Romagnani S: Human Th17 cells. Arthritis
Res Ther. 10:2062008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iwakura Y, Nakae S, Saijo S and Ishigame
H: The roles of IL-17A in inflammatory immune responses and host
defense against pathogens. Immunol Rev. 226:57–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Søndergaard H and Skak K: IL-21: Roles in
immunopathology and cancer therapy. Tissue Antigens. 74:467–479.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geboes L, Dumoutier L, Kelchtermans H,
Schurgers E, Mitera T, Renauld JC and Matthys P: Proinflammatory
role of the Th17 cytokine interleukin-22 in collagen-induced
arthritis in C57BL/6 mice. Arthritis Rheum. 60:390–395. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zenewicz LA and Flavell RA: IL-22 and
inflammation: Leukin' through a glass onion. Eur J Immunol.
38:3265–3268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duhen T, Geiger R, Jarrossay D,
Lanzavecchia A and Sallusto F: Production of interleukin 22 but not
interleukin 17 by a subset of human skin-homing memory T cells. Nat
Immunol. 10:857–863. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin-Orozco N, Muranski P, Chung Y, Yang
XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW and Dong C: T
helper 17 cells promote cytotoxic T cell activation in tumor
immunity. Immunity. 31:787–798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Yi T, Kortylewski M, Pardoll DM,
Zeng D and Yu H: IL-17 can promote tumor growth through an
IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kryczek I, Banerjee M, Cheng P, Vatan L,
Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et
al: Phenotype, distribution, generation, and functional and
clinical relevance of Th17 cells in the human tumor environments.
Blood. 114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM,
Hoft DF and Peng G: Human tumor-infiltrating Th17 cells have the
capacity to differentiate into IFN-γ+ and
FOXP3+ T cells with potent suppressive function. Eur J
Immunol. 41:936–951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fialová A, Partlová S, Sojka L, Hromádková
H, Brtnický T, Fučíková J, Kocián P, Rob L, Bartůňková J and Spíšek
R: Dynamics of T-cell infiltration during the course of ovarian
cancer: The gradual shift from a Th17 effector cell response to a
predominant infiltration by regulatory T-cells. Int J Cancer.
132:1070–1079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyahara Y, Odunsi K, Chen W, Peng G,
Matsuzaki J and Wang RF: Generation and regulation of human
CD4+ IL-17-producing T cells in ovarian cancer. Proc
Natl Acad Sci USA. 105:15505–15510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muranski P, Boni A, Antony PA, Cassard L,
Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K,
et al: Tumor-specific Th17-polarized cells eradicate large
established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tartour E, Fossiez F, Joyeux I, Galinha A,
Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V,
et al: Interleukin 17, a T-cell-derived cytokine, promotes
tumorigenicity of human cervical tumors in nude mice. Cancer Res.
59:3698–3704. 1999.PubMed/NCBI
|
|
15
|
Lan C, Huang X, Lin S, Huang H, Cai Q, Lu
J and Liu J: High density of IL-17-producing cells is associated
with improved prognosis for advanced epithelial ovarian cancer.
Cell Tissue Res. 352:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brandt K, Bulfone-Paus S, Foster DC and
Rückert R: Interleukin-21 inhibits dendritic cell activation and
maturation. Blood. 102:4090–4098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Veldhoen M, Hirota K, Westendorf AM, Buer
J, Dumoutier L, Renauld JC and Stockinger B: The aryl hydrocarbon
receptor links TH17-cell-mediated autoimmunity to
environmental toxins. Nature. 453:106–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huber S, Gagliani N, Zenewicz LA, Huber
FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, et
al: IL-22BP is regulated by the inflammasome and modulates
tumorigenesis in the intestine. Nature. 491:259–263. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sabat R, Ouyang W and Wolk K: Therapeutic
opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov.
13:21–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Caproni M, Antiga E, Melani L, Volpi W,
Del Bianco E and Fabbri P: Serum levels of IL-17 and IL-22 are
reduced by etanercept, but not by acitretin, in patients with
psoriasis: A randomized-controlled trial. J Clin Immunol.
29:210–214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiang T, Long H, He L, Han X, Lin K, Liang
Z, Zhuo W, Xie R and Zhu B: Interleukin-17 produced by tumor
microenvironment promotes self-renewal of CD133+ cancer
stem-like cells in ovarian cancer. Oncogene. 34:165–176. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kryczek I, Lin Y, Nagarsheth N, Peng D,
Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, et al:
IL-22+CD4+ T cells promote colorectal cancer
stemness via STAT3 transcription factor activation and induction of
the methyltransferase DOT1L. Immunity. 40:772–784. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gogacz M, Winkler I, Bojarska-Junak A,
Tabarkiewicz J, Semczuk A, Rechberger T and Adamiak A: Increased
percentage of Th17 cells in peritoneal fluid is associated with
severity of endometriosis. J Reprod Immunol. 117:39–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei L, Laurence A, Elias KM and O'Shea JJ:
IL-21 is produced by Th17 cells and drives IL-17 production in a
STAT3-dependent manner. J Biol Chem. 282:34605–34610. 2007.
View Article : Google Scholar : PubMed/NCBI
|
